Search Results - "Craine, Veronica"

Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma by Motzer, Robert J, Powles, Thomas, Atkins, Michael B, Escudier, Bernard, McDermott, David F, Alekseev, Boris Y, Lee, Jae-Lyun, Suarez, Cristina, Stroyakovskiy, Daniil, De Giorgi, Ugo, Donskov, Frede, Mellado, Begoña, Banchereau, Romain, Hamidi, Habib, Khan, Omara, Craine, Veronica, Huseni, Mahrukh, Flinn, Nick, Dubey, Sarita, Rini, Brian I

“…Interim analyses of the IMmotion151 trial (A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced…”
Get more information

INAVO121: Phase III study of inavolisib (INAVO) + fulvestrant (FUL) vs. alpelisib (ALP) + FUL in patients (pts) with hormone receptor-positive, HER2-negative (HR+, HER2–) PIK3CA -mutated (mut) locally advanced or metastatic breast cancer (LA/mBC) by Juric, Dejan, Kalinsky, Kevin, Im, Seock-Ah, Ciruelos, Eva M, Bianchini, Giampaolo, Barrios, Carlos H., Jacot, William, Schmid, Peter, Loi, Sherene, Rugo, Hope S., Craine, Veronica, Hutchinson, Katherine E., Flechais, Aulde, Thanopoulou, Eirini, Harbeck, Nadia

“…TPS1123 Background: Standard-of-care (SoC) endocrine therapy (ET) for pts with HR+, HER2– LA/mBC was transformed by combinations with cyclin-dependent kinase…”
Get full text

Subgroup analysis of elderly patients (pts) with diffuse large B-cell lymphoma (DLBCL) in the phase 3 POLARIX study by Hu, Bei, Reagan, Patrick Michael, Sehn, Laurie Helen, Sharman, Jeff Porter, Hertzberg, Mark, Zhang, Huilai, Kim, Austin Injae, Herbaux, Charles, Molina, Lysiane, Maruyama, Dai, Smolewski, Piotr, Stenner, Frank, Craine, Veronica, Kothari, Rucha, Hirata, Jamie H., Sahin, Deniz, Sugidono, Matthew Dean Sei, Lee, Calvin, Tilly, Herve

“…7518 Background: In the Phase 3 POLARIX study (NCT03274492), polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP)…”
Get full text

Patient- versus clinician-reported symptoms in the POLARIX study by Thompson, Carrie A., Mehta-Shah, Neha, Flowers, Christopher, Salles, Gilles A., Tilly, Herve, Chua, Neil Sun, Casasnovas, René-Olivier, Miall, Fiona, Kim, Tae Min, Tsai, Cheng-Hong, Nasta, Sunita Dwivedy, Lee, Seung Tae, Craine, Veronica, Campinha-Bacote, Avrita, Hirata, Jamie H., Lee, Calvin, Sugidono, Matthew Dean Sei, Friedberg, Jonathan W.

“…12100 Background: The safety profiles of novel agents are mainly based on clinician-reported adverse events (AEs) from clinical trials. Patient-reported…”
Get full text

Abstract CT188: IMmotion151: updated overall survival (OS) and exploratory analysis of the association of gene expression and clinical outcomes with atezolizumab plus bevacizumab vs sunitinib in patients with locally advanced or metastatic renal cell carcinoma (mRCC) by Rini, Brian I., Atkins, Michael B., Escudier, Bernard, Powles, Thomas, McDermott, David F., Alekseev, Boris Y., Lee, Jae-Lyun, Stroyakovskiy, Daniil, Rodriguez, Cristina Suarez, De Giorgi, Ugo, Donskov, Frede, Mellado, Begoña, Banchereau, Romain, Hamidi, Habib, Khan, Omara, Craine, Veronica, Huseni, Mahrukh, Flinn, Nick, Dubey, Sarita, Motzer, Robert

“…Abstract Background: In IMmotion151 (NCT02420821), atezo (anti-PD-L1) + bev (anti-VEGF) improved PFS vs sun as 1L treatment in patients (pts) with mRCC (Rini,…”
Get full text

Phase 1 Study of CD19 Targeted 4-1BBL Costimulatory Agonist to Enhance T Cell (Glofitamab Combination) or NK Cell Effector Function (Obinutuzumab Combination) in Relapsed/Refractory B Cell Lymphoma by Hutchings, Martin, Offner, Fritz C., Bosch, Francesc, Gritti, Giuseppe, Carlo-Stella, Carmelo, Walter, Harriet, Townsend, William, Morschhauser, Franck, Cartron, Guillaume, Ghesquieres, Hervé, de Guibert, Sophie, Herter, Sylvia, Korfi, Koorosh, Craine, Veronica, Mycroft, Sarah Louise, Whayman, Matt, Mueller, Claudia, Dimier, Natalie, Moore, Tom, Belli, Sara, Kornacker, Martin, Lechner, Katharina, Dickinson, Michael

“…Background: Up to 50% of patients suffering from Non-Hodgkin's lymphoma (NHL) become refractory to or relapse after treatment (M. Crump, Blood 2017). With…”
Get full text

Abstract PO2-19-08: INAVO121: Phase III study of inavolisib + fulvestrant vs alpelisib + fulvestrant in patients with hormone receptor-positive, HER2-negative, PIK3CA-mutated locally advanced or metastatic breast cancer by Juric, Dejan, Kalinsky, Kevin, Im, Seock-Ah, Ciruelos, Eva, Bianchini, Giampaolo, Barrios, Carlos, Jacot, William, Schmid, Peter, Loi, Sherene, Rugo, Hope, Craine, Veronica, Hutchinson, Katherine, Flechais, Aulde, Thanopoulou, Eirini, Harbeck, Nadia

“…Abstract BACKGROUND Standard-of-care (SoC) endocrine therapy (ET) for patients (pts) with hormone receptor-positive, HER2-negative, PIK3CA-mutated locally…”
Get full text